cat epidermis allergen
Approved
Mar 13, 1924
Allergies to cats, a type of animal allergy, is one of the most common allergies experienced by humans. Among the eight known cat allergens, the most prominent allergen is secretoglobin Fel d 1, which is produced in the anal glands, salivary glands, and, mainly, in sebaceous glands of cats, and is ubiquitous in the United States, even in households without cats. Due to cats' grooming habits, the saliva is distributed to other areas of the animal, such as the hair and skin, increasing the impact of the allergen. The second most common is Fel d 2; this type is triggered by airborne dead skin flakes (dander) and their presence in the smell of cat urine. — Wikipedia
Clinical trial activity
23 trials · 24 clinical orgs · 4 marketing orgs
Earliest trial started May 1, 2006 (NCT00346398)
Timeline
1920s
- Mar 13, 1924
Jubilant Innovation Ltd. — Earliest FDA Approval
- Mar 13, 1924
Jubilant Innovation Ltd. — NDA Secondary Org
- Mar 13, 1924
Jubilant Innovation Ltd. — NDA Organization
1930s
- Jul 11, 1930
ALK-Abello, S.A. — NDA Secondary Org
1950s
- Sep 15, 1958
Greer Laboratories — NDA Secondary Org
1970s
- Mar 12, 1974
Allermed Laboratories — NDA Secondary Org
2010s
- Jan 1, 2012
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Felis catusImmunity, desensitized
Felis catus immunity, desensitized
Approval history
- approvedMar 13, 1924
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAllergy to cats ↗
- NCATS5308ED00EL ↗
- WikipediaAllergy_to_cats ↗
Also known as
- cat allergen
- cat hair allergen
- cat hair allergenic extract
- felis domesticus allergen
- standardized epidermals cat hair (felis domesticus)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06828484 | N/A | Mar 4, 2025 | Queen's University, Belfast |
| NCT04035109 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2019 | National Heart, Lung, and Blood Institute (NHLBI), University of North Carolina at Chapel Hill |
| NCT03780387 | Early Phase 1 (Phase 1) | Apr 16, 2019 | National Heart, Lung, and Blood Institute (NHLBI), University of North Carolina at Chapel Hill |
| NCT03031145 | Phase 1 | Apr 3, 2017 | National Heart, Lung, and Blood Institute (NHLBI), University of North Carolina at Chapel Hill |
| NCT02665754 | Phase 1 | Jul 1, 2016 | Gachon University, Korea Research Foundation |
| NCT02163122 | Early Phase 1 (Phase 1) | Jan 1, 2015 | Immune Tolerance Network, Inflamax, National Institute of Allergy and Infectious Diseases (NIAID), University of London |
| NCT02311413 | Phase 2 | Jan 1, 2015 | Circassia Limited, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02237196 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2014 | Immune Tolerance Network, National Institute of Allergy and Infectious Diseases (NIAID), University of California, Los Angeles |
| NCT02269566 | Phase 1 | Aug 1, 2014 | Gachon University, Thermo Fisher Scientific |
| NCT02301884 | Phase 1 | Nov 1, 2013 | Gachon University, Thermo Fisher Scientific |
| NCT01921257 | Phase 2 | Aug 1, 2013 | Circassia Limited, inVentiv |
| NCT01620762 | Phase 3 | Oct 1, 2012 | Circassia Limited, inVentiv, Jewish National Health, Pharm-Olam International |
| NCT01547286 | N/A | May 1, 2012 | Harvard University, National Heart, Lung, and Blood Institute (NHLBI) |
| NCT01383603 | Phase 1 | Oct 1, 2011 | Adiga Life Sciences, Inc., Circassia Limited |
| NCT01383590 | Phase 1 | Oct 1, 2011 | Adiga Life Sciences, Inc., Circassia Limited |
| NCT01292070 | Early Phase 1 (Phase 1) | Mar 1, 2011 | Immune Tolerance Network, National Institute of Allergy and Infectious Diseases (NIAID), Tunitas Therapeutics, Inc., University of California, Los Angeles |
| NCT01033344 | Phase 2 | Jan 1, 2010 | Adiga Life Sciences, Inc., Circassia Limited, PRACS |
| NCT00987909 | Phase 2 | Sep 1, 2009 | ALK-Abello, S.A., PRACS |
| NCT00867906 | Phase 2 | Mar 1, 2009 | Adiga Life Sciences, Inc., Alpha Medical Research, Circassia Limited |
| NCT00689299 | Phase 2 | Oct 1, 2008 | Antigen Laboratories, Inc. |
Organizations
Research & Development (24)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Circassia Limited | For profit | 9 | 8 | 3 | 2008 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 5 | 5 | 2 | 2006 |
| Adiga Life Sciences, Inc. | For profit | 4 | 0 | 2 | 2009 |
| Immune Tolerance Network | Academic/Hospital | 4 | 0 | 2 | 2006 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 4 | 0 | 3 | 2012 |
| Gachon University | Academic/Hospital | 3 | 3 | 1 | 2013 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 3 | 3 | 2 | 2017 |
| inVentiv | For profit | 2 | 0 | 2 | 2012 |
| PRACS | For profit | 2 | 0 | 1 | 2009 |
| Thermo Fisher Scientific | For profit | 2 | 0 | 1 | 2013 |
| University of California, Los Angeles | Academic/Hospital | 2 | 0 | 2 | 2011 |
| ALK-Abello, S.A. | For profit | 1 | 1 | 1 | 2009 |
| Allied Research International | For profit | 1 | 0 | 1 | 2008 |
| Alpha Medical Research | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Antigen Laboratories, Inc. | For profit | 1 | 1 | 1 | 2008 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Inflamax | For profit | 1 | 0 | 1 | 2015 |
| Jewish National Health | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Korea Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Pharm-Olam International | For profit | 1 | 0 | 1 | 2012 |
Marketing (5)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ALK-Abello, S.A. | For profit | NDA2 | Jul 11, 1930 |
| Allermed Laboratories | For profit | NDA2 | Mar 12, 1974 |
| Greer Laboratories | For profit | NDA2 | Sep 15, 1958 |
| Jubilant Innovation Ltd. | For profit | NDA2 | Mar 13, 1924 |
| Jubilant Innovation Ltd. | For profit | NDA | Mar 13, 1924 |